V.le Fulvio Testi, 330
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies.
13 articles about Italfarmaco
Italfarmaco Group announced that the U.S. Food and Drug Administration has extended the review process of the New Drug Application for Givinostat, the company’s proprietary histone deacetylase inhibitor for the treatment of Duchenne Muscular Dystrophy.
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
Italfarmaco Group announced that its Marketing Authorization Application for Givinostat as a potential treatment for Duchenne Muscular Dystrophy has been submitted to the European Medicine Agency and that the EMA has started its regulatory review process.
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
Italfarmaco Group announced that the U.S. Food and Drug Administration has completed its filing review and accepted the company’s New Drug Application for Givinostat.
Italfarmaco Acquires 100% of Lacer, a Spanish Pharmaceutical Company That Is a Leader in Health Care and Personal Hygiene
Italfarmaco, an Italian multinational company in the chemical-pharmaceutical sector, has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the area of health and personal hygiene.
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
Italfarmaco Group announced positive topline data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase inhibitor, in boys with Duchenne Muscular Dystrophy.
Italfarmaco Announces Topline Data from Phase 2 Trial with Givinostat in Patients with Becker Muscular Dystrophy
Italfarmaco Group announced topline data from its proof-of-concept Phase 2 trial with Givinostat, the company’s proprietary histone deacetylase inhibitor, in 51 adult males with Becker Muscular Dystrophy.
Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries
Italfarmaco Group adds innovative Alzheimer’s disease therapy to its neurology-based product portfolio
Italfarmaco Provides Update on Ongoing Clinical Programs with Givinostat in Oral Presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy
Analyses of long-term study with Givinostat in Duchenne Muscular Dystrophy boys continue to show delayed disease progression
Italfarmaco Receives FDA Rare Pediatric Disease Designation for Givinostat in Duchenne Muscular Dystrophy, Announces Completed Enrollment in EPIDYS Phase 3 Trial
The Italfarmaco Group provided an update on the development of Givinostat, its proprietary histone deacetylase inhibitor, in boys with Duchenne Muscular Dystrophy.
Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne Muscular Dystrophy
The Italfarmaco Group provided an update on the clinical development program of Givinostat, its proprietary histone deacetylase inhibitor, in Duchenne Muscular Dystrophy.
Italfarmaco Enters Binding Term Sheet Agreement With Neupharma for an Exclusive Option to Develop and Commercialize Inhaled Teicoplanin
Italfarmaco Group announced that Italfarmaco SpA, a member company, has entered into a binding term sheet agreement with Neupharma for an exclusive option to develop and commercialize inhaled teicoplanin.
Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.